Live
IlluminaIs It Time To Reassess Illumina (ILMN) After Its Recent Share Price Volatility? - simplywall.stFierceBiotechGilead cancels midstage HIV trial as FDA’s clinical hold remains intactEndpoints NewsGilead ends a Phase 2/3 trial of long-acting HIV pillsLonza NewsLonza releases annual report - The Vacaville ReporterBioPharma DiveBiogen, on the heels of a $5.6B buyout, turns its sights to early-stage assetsEndpoints NewsNoom plans push into peptides beyond weight loss drugsFierceBiotechThousands of clinical trial sites impacted by Middle East conflict: reportFierceBiotechDrug combo treats multiple cancers with ‘paradox’ mutation in miceFierceBiotechValneva CEO on Pfizer-partnered Lyme vaccine: Why a phase 3 miss doesn’t tell the whole storyAgilentSynthego Welcomes Supreme Court Order Finalizing Invalidation of Agilent CRISPR Patents - PR NewswireEndpoints NewsMaking custom CRISPR therapies could be harder than initially thoughtEndpoints NewsTo counter China, FDA chief wants to speed new drug trial process
Waters Feb 10, 2026

Waters Corporation (WAT) Reports Strong Q4 2025 Results and Prom - GuruFocus

Waters Corporation (WAT) Reports Strong Q4 2025 Results and Prom - GuruFocus

Original
Body unavailable. Use the original source.

Directory

59 All